Literature DB >> 19521695

Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis.

Michele D Mignogna, Giulio Fortuna, Jessica Falleti, Stefania Leuci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19521695     DOI： 10.1007/s00228-009-0674-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  13 in total

1.  Local and systemic implications of thymidine catabolism by human keratinocytes.

Authors:  P M Schwartz; H Reuveni; L M Milstone
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

2.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 3.  Capecitabine: a review.

Authors:  Christine M Walko; Celeste Lindley
Journal:  Clin Ther       Date:  2005-01       Impact factor: 3.393

4.  Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.

Authors:  J M Joulia; F Pinguet; M Ychou; J Duffour; C Astre; F Bressolle
Journal:  Eur J Cancer       Date:  1999-02       Impact factor: 9.162

5.  The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy.

Authors:  M Janusch; M Fischer; W Ch Marsch; H-J Holzhausen; T Kegel; P Helmbold
Journal:  Eur J Dermatol       Date:  2006 Sep-Oct       Impact factor: 3.328

6.  Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.

Authors:  Jean-Louis Fischel; Patricia Formento; Joseph Ciccolini; Marie-Christine Etienne-Grimaldi; G Milano
Journal:  Anticancer Drugs       Date:  2004-11       Impact factor: 2.248

7.  Candidate mechanisms for capecitabine-related hand-foot syndrome.

Authors:  Gérard Milano; Marie-Christine Etienne-Grimaldi; Mireille Mari; Sandra Lassalle; Jean-Louis Formento; Mireille Francoual; Jean-Philippe Lacour; Paul Hofman
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

8.  Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.

Authors:  Akio Ooyama; Toshinori Oka; Hong-ye Zhao; Masatatsu Yamamoto; Shin-ichi Akiyama; Masakazu Fukushima
Journal:  Cancer Lett       Date:  2008-04-16       Impact factor: 8.679

9.  FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

Authors:  Qin Ryan; Amna Ibrahim; Martin H Cohen; John Johnson; Chia-wen Ko; Rajeshwari Sridhara; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2008-10-10

10.  Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.

Authors:  T Ernst; K Merx; U Gnad-Vogt; N Lukan; M Kripp; B Schultheis; A Hochhaus; R-D Hofheinz
Journal:  Br J Cancer       Date:  2007-11-13       Impact factor: 7.640
View more
  3 in total

Review 1.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

2.  Photosensitive lichenoid skin reaction to capecitabine.

Authors:  Rena A Shah; Daniel D Bennett; Mark E Burkard
Journal:  BMC Cancer       Date:  2017-12-19       Impact factor: 4.430

3.  Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine.

Authors:  Hua Xing; Lirong Zhang; Jinshu Ma; Zhen Liu; Changlong Song; Yuxia Liu
Journal:  Front Pharmacol       Date:  2018-05-23       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.